youtube_live
Q4 2026 earnings • released • EPS miss -1.20% • Revenue miss -39.67%
See resultschevron_right
ARWR:NASDAQ
Arrowhead Pharmaceuticals Inc
$44.83
arrow_downward
-6.17%(-2.95) 1D
Nov 16, 3:14:14 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARWR...
Open
$47.12
High
$47.40
Low
$44.38
Mkt. cap
6.34B
Avg. vol.
2.03M
Volume
1.02M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$5.11
Beta
1.34
Shares outstanding
141.37M
No. of employees
1K
Open
$47.12
High
$47.40
Low
$44.38
Mkt. cap
6.34B
Avg. vol.
2.03M
Volume
1.02M
52-wk high
$95.49
52-wk low
$37.06
EPS
-$5.11
Beta
1.34
Shares outstanding
141.37M
No. of employees
1K
News stories
From web sources and news partners
The Pharma Letter
·
3 hours ago
Arrowhead shares end week down 18% after Ionis’s Tryngolza stumble casts doubt on sHTG launch
Profile
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
About Arrowhead Pharmaceuticals Inc
CEOChristopher Richard Anzalone
Employees1.06K
FoundedJan 1, 2004
HeadquartersPasadena, California, United States
SectorHealth Care
IndustryBiotechnology
Websitearrowheadpharma.com
Analyst ratings
Based on 12 analysts giving stock ratings to ARWR in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ARWR in the last 3 months.
Highest
Current $44.83
$126.00 (+181.06%)
Average
$106.89 (+138.43%)
Lowest
$74.00 (+65.07%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Jason Gerberry Bank of America Securities | Buy | Maintained | - | - | 11/13/2026 |
Luca Issi RBC Capital | Buy | Reiterated | $100.00 | +123.1% | 11/13/2026 |
Michael Ulz Morgan Stanley | Buy | Maintained | $106.00 | +136.4% | 11/13/2026 |
Unknown Analyst UBS | Buy | Reiterated | $109.00 | +143.1% | 11/13/2026 |
James Condulis Stifel Nicolaus | Buy | Maintained | $96.00 | +114.1% | 11/13/2026 |
Edward Tenthoff Piper Sandler | Buy | Reiterated | $126.00 | +181.1% | 11/13/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $120.00 | +167.7% | 11/11/2026 |
Madison Elsaadi B. Riley Securities | Buy | Maintained | $123.00 | +174.4% | 11/10/2026 |
Brian Cheng J.P. Morgan | Buy | Reiterated | - | - | 10/15/2026 |
Eric Joseph Citi | Buy | Maintained | $108.00 | +140.9% | 10/14/2026 |
Joon Lee UBS | Buy | Reiterated | $109.00 | +143.1% | 10/15/2026 |
Andrea Newkirk Goldman Sachs | Hold | Initiated | $74.00 | +65.1% | 09/24/2026 |
Joseph Thome TD Cowen | Buy | Maintained | - | - | 08/30/2026 |
Keay Nakae Chardan Capital | Buy | Maintained | $115.00 | +156.5% | 08/04/2026 |
William Pickering Bernstein | Hold | Reiterated | $46.00 | +2.6% | 05/13/2026 |
Mani Foroohar Leerink Partners | Hold | Maintained | - | - | 03/26/2026 |
Last report
Nov 12, 2026
Fiscal period
Q4 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$1.52 / -$1.50
-1.20%miss
arrow_downward
Revenue / Est. (USD)
37.79M / 62.64M
-39.67%miss
arrow_downward
Fiscal Q4 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 264.03M | 73.74M | 75.25M | 37.79M |
Cost of goods sold | - | - | - | 1.80M |
Cost of revenue | - | - | - | 1.80M |
Research and development expenses | 173.52M | 165.66M | 191.21M | 197.82M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 49.70M | 49.34M | 54.14M | 274.80M |
Operating expense | 223.22M | 215.00M | 245.35M | 472.62M |
Total operating expenses | 223.22M | 215.00M | 245.35M | 474.42M |
Operating income | 40.81M | -141.26M | -170.09M | -436.63M |
Other non operating income | 277.00K | -1.61M | 1.28M | 4.03M |
EBT including unusual items | 28.27M | -137.56M | -178.90M | -435.71M |
EBT excluding unusual items | 28.27M | -156.56M | -178.90M | -435.71M |
Income tax expense | 29.00K | 7.00K | 11.00K | -6.83M |
Effective tax rate | 0.10% | -0.01% | -0.01% | 1.57% |
Other operating expenses | - | - | - | - |
Net income | 30.81M | -132.73M | -194.28M | -428.00M |
Net profit margin | 11.67% | -180.01% | -258.17% | -1,132.46% |
Earnings per share | 0.22 | -0.93 | -1.36 | -1.52 |
Interest and investment income | 9.69M | 16.87M | 16.94M | 14.37M |
Interest expense | -22.50M | -23.85M | -24.56M | -22.80M |
Net interest expenses | -12.82M | -6.98M | -7.63M | -8.43M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 47.20M | -134.89M | -163.43M | -429.42M |
Gain or loss from assets sale | - | -19.00M | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events